JP7817241B2 - ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド - Google Patents

ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド

Info

Publication number
JP7817241B2
JP7817241B2 JP2023512724A JP2023512724A JP7817241B2 JP 7817241 B2 JP7817241 B2 JP 7817241B2 JP 2023512724 A JP2023512724 A JP 2023512724A JP 2023512724 A JP2023512724 A JP 2023512724A JP 7817241 B2 JP7817241 B2 JP 7817241B2
Authority
JP
Japan
Prior art keywords
antibody
seq
light chain
heavy chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023512724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023539581A5 (https=
JP2023539581A (ja
JPWO2022042673A5 (https=
Inventor
松涛 周
洵 劉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Original Assignee
Shanghai Hengrui Pharmaceutical Co Ltd
Jiangsu Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Hengrui Pharmaceutical Co Ltd, Jiangsu Hengrui Pharmaceutical Co Ltd filed Critical Shanghai Hengrui Pharmaceutical Co Ltd
Publication of JP2023539581A publication Critical patent/JP2023539581A/ja
Publication of JP2023539581A5 publication Critical patent/JP2023539581A5/ja
Publication of JPWO2022042673A5 publication Critical patent/JPWO2022042673A5/ja
Application granted granted Critical
Publication of JP7817241B2 publication Critical patent/JP7817241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023512724A 2020-08-28 2021-08-27 ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド Active JP7817241B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010882873 2020-08-28
CN202010882873.5 2020-08-28
CN202110958128 2021-08-20
CN202110958128.9 2021-08-20
PCT/CN2021/114911 WO2022042673A1 (zh) 2020-08-28 2021-08-27 用于降低异源多肽末端异质性的信号肽

Publications (4)

Publication Number Publication Date
JP2023539581A JP2023539581A (ja) 2023-09-15
JP2023539581A5 JP2023539581A5 (https=) 2025-10-30
JPWO2022042673A5 JPWO2022042673A5 (https=) 2025-10-30
JP7817241B2 true JP7817241B2 (ja) 2026-02-18

Family

ID=80352714

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023512724A Active JP7817241B2 (ja) 2020-08-28 2021-08-27 ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド

Country Status (7)

Country Link
US (1) US20230312725A1 (https=)
EP (1) EP4206222A4 (https=)
JP (1) JP7817241B2 (https=)
CN (1) CN116234814A (https=)
CA (1) CA3191184A1 (https=)
TW (1) TWI889889B (https=)
WO (1) WO2022042673A1 (https=)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539347A (ja) 2006-06-02 2009-11-19 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2015028057A (ja) 2007-11-02 2015-02-12 ザ ジョンズ ホプキンス ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法
US20150225482A1 (en) 2012-10-12 2015-08-13 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
WO2021160116A1 (zh) 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2182498A1 (en) * 1994-02-01 1995-08-10 William J. Larochelle Fusion proteins that include antibody and nonantibody portions
IL140110A0 (en) * 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2003237332A1 (en) * 2002-06-03 2003-12-19 Centocor, Inc. Anti-relp fusion antibodies, compositions, methods and uses
AR047440A1 (es) * 2004-01-21 2006-01-18 Novozymes As Produccion de un anticuerpo monoclonal en un hongo heterocarion o una celula huesped fungal
CN101375161A (zh) * 2006-01-27 2009-02-25 默克公司 靶定金黄色葡萄球菌ORF0657n的抗原结合蛋白
CN101460520B (zh) * 2006-06-02 2012-12-26 Aveo制药公司 肝细胞生长因子(hgf)的结合蛋白质
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539347A (ja) 2006-06-02 2009-11-19 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
JP2015028057A (ja) 2007-11-02 2015-02-12 ザ ジョンズ ホプキンス ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法
US20150225482A1 (en) 2012-10-12 2015-08-13 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
WO2021160116A1 (zh) 2020-02-10 2021-08-19 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Biotechnology and Bioengineering，2017年，Vol.114, No.9，pp.1970-1977
Haryadi R et al.，Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells，PLOS ONE, [online]，2018年，pp.1-16，[取得日 2025/07/14], 取得先<https://doi.org/10.1371/journal.pone.0116878>

Also Published As

Publication number Publication date
TW202227482A (zh) 2022-07-16
US20230312725A1 (en) 2023-10-05
WO2022042673A1 (zh) 2022-03-03
EP4206222A1 (en) 2023-07-05
CN116234814A (zh) 2023-06-06
TWI889889B (zh) 2025-07-11
EP4206222A4 (en) 2024-04-10
CA3191184A1 (en) 2022-03-03
JP2023539581A (ja) 2023-09-15

Similar Documents

Publication Publication Date Title
US11149094B2 (en) Engineered multispecific antibodies and other multimeric proteins with asymmetrical CH2-CH3 region mutations
TWI798179B (zh) 多特異性抗體之純化
US12415859B2 (en) Methods of producing heterodimeric antibodies
JP7817241B2 (ja) ヘテロポリペプチドの末端異質性を低減するためのシグナルペプチド
AU2020268399B2 (en) Methods of making antibodies
RU2804031C2 (ru) Сконструированные мультиспецифические антитела и другие мультимерные белки с асимметричными мутациями в области ch2-ch3
CA3191328A1 (en) Purification of multispecific antibodies

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20231222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250723

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260127

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260205

R150 Certificate of patent or registration of utility model

Ref document number: 7817241

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150